Earnings call transcript: Cibus Q2 2025 sees stock rise 3.52% post-call

Cibus Inc. (NASDAQ:CBUS) reported its second-quarter 2025 earnings with revenue reaching $933,000, marking an increase from $838,000 in the same period last year. Despite a net loss of $26.6 million, the company showed improvements compared to a $28.5 million loss the previous year. Following the earnings call, Cibus’ stock rose by 3.52% in aftermarket trading, reflecting investor optimism about the company’s strategic initiatives and cost management efforts. According to InvestingPro data, the company’s revenue growth has been substantial, showing a 104.78% increase over the last twelve months, though analysis indicates the company is currently burning through cash at a concerning rate.

Key Takeaways

• Cibus reported a 3.52% increase in its stock price in aftermarket trading.
• Revenue for Q2 2025 was $933,000, up from $838,000 year-over-year.
• The company reduced its R&D and SG&A expenses, improving its financial position.
• Cibus anticipates initial revenues from its biofragrance program in late 2025.

Company Performance

Cibus demonstrated resilience in the second quarter of 2025, with revenue growth and reduced operational expenses. The company has focused on streamlining its operations and prioritizing key programs, which may have contributed to the positive market response. The gene editing agriculture market, where Cibus operates, continues to expand globally, providing a favorable backdrop for the company’s endeavors.

Financial Highlights

• Revenue: $933,000, up from $838,000 in Q2 2024.
• Net Loss: $26.6 million, improved from $28.5 million last year.
• R&D Expense: $12.2 million, down from $13 million year-over-year.
• SG&A Expense: $6.6 million, down from $9.3 million year-over-year.
• Cash and Cash Equivalents: $36.5 million as of June 30, 2025.

Market Reaction

Cibus’ stock experienced a 3.52% increase in aftermarket trading, reaching a price of $1.45. This movement comes after a previous close at $1.42, suggesting positive investor sentiment towards the company’s strategic focus and cost management. The stock remains near its 52-week low of $1.36, indicating potential room for growth as the company pursues its long-term initiatives.

Outlook & Guidance

Cibus has outlined several strategic initiatives, including the commercialization of its rice herbicide tolerance traits in Latin America by 2027 and in the U.S. by 2028. The company also expects nominal revenues from its biofragrance program by late 2025, with a full commercial ramp-up anticipated in 2026. These initiatives, coupled with a focus on reducing cash usage to $30 million annually by 2026, provide a roadmap for future growth.

Executive Commentary

Peter Beetham, CEO of Cibus, emphasized the company’s commitment to advancing gene editing in agriculture, stating, "Gene editing has a clear path to industrialized breeding. And it’s not for the future. It’s actually happening now." Greg Gochel, CSO, highlighted the company’s technological capabilities, noting, "We’re excited for the complexity of the edits that we can make and the single cell system that enables us to keep those edits together."

Risks and Challenges

• Regulatory hurdles remain a potential challenge, though Cibus expects an EU regulatory resolution within six months.
• Market acceptance of bio-based products could impact revenue projections.
• The company’s ability to manage cash flow and reduce expenses will be crucial for sustaining operations.

Q&A

During the earnings call, analysts inquired about the potential for higher royalty pricing on quality traits, such as nonallergenic crops. Cibus confirmed that its biofragrance revenues will initially focus on a single customer, with expansion plans in place. The company also addressed questions regarding its operational focus and cost management strategies.

Cibus’ strategic initiatives and improved financial metrics have positioned the company for potential growth, as reflected in the positive market reaction following its Q2 2025 earnings call.

Full transcript - Cibus Inc (CBUS) Q2 2025:

Conference Operator: Afternoon, and welcome to the CEVA Second Quarter twenty twenty five Results Conference Call. All participants will be in a listen only mode. After today’s presentation, there will be an opportunity to ask questions. Please also note today’s event is being recorded. At this time, I would like to turn the conference over to Carlo Bruich, Interim Chief Financial Officer.

Please go ahead.

Carlo Bruich, Interim Chief Financial Officer, CBIS: Thank you, and good afternoon. I would like to thank you for taking time to join us for CBI’s second quarter twenty twenty five financial results and business update conference call and webcast. Presenting with me today is Peter Beethen, Co Founder, Interim Chief Executive Officer, President and COO and Greg Gochel, Co Founder and our Chief Scientific Officer. Before we begin the call, I’d like to remind everyone that statements made on the call and webcast, including those regarding future financial results and future operational goals and industry prospects are forward looking and may be subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the call. Please refer to CBIZ SEC filings for a list of associated risks.

This conference call is being webcast. The webcast link along with our press release and corporate presentation are available on the Investor Relations section of cbiz.com to assist you in your analysis of our business. And with that, I would now like to turn the call over to Peter.

Peter Beetham, Co-Founder, Interim CEO, President and COO, CBIS: Thanks, Carlo, and good afternoon to everyone. I’d like to start today’s call to recognize that our team here at CBIS remains laser focused on delivering our targeted near term revenues. Our second quarter demonstrates continued execution toward our commercial objectives, with clear progress across our focus programs in rice and partner funded and or supported sustainable ingredients, including biofragrances, that are positioning CBIS to begin recognizing initial revenue in 2026. Every quarter, we are getting closer to that pivotal initial revenue moment through tangible commercial progress, which includes successful field trials, milestone achievements, regulatory clearances, and direct customer engagement. The path to revenue is really clear.

Let me be even more specific about what we’re building toward. Our RIOS herbicide tolerance traits, HT1 and HT3 alone, represent over $200,000,000 in potential annual royalty revenue across our initial target geographies in The United States and Latin America. These traits are progressing on schedule toward targeted initial launches in Latin America beginning in 2027 and expanding to The United States in 2028, which would generate initial royalty revenue and set the stage for further opportunities in the immense global rice feed market. This pursuit doesn’t represent a distant aspiration. Rather, this is the reality of our near term commercial opportunities.

We believe we are developing a new industrial plant breeding platform. We have traits moving into customer germplasm. We’re seeing positive results in field trials, and we’re witnessing an increasingly accepting global regulatory environment that’s opening doors for customer engagement and market penetration opportunities that simply didn’t exist before. As we advance towards revenue generation, we’re taking a disciplined and strategic approach to capital allocation that maximizes our near term commercial opportunities while preserving the significant value we’ve created across our broader trait portfolio. The streamlined operational focus we just announced in July concentrates our resources on our rice herbicide tolerance traits, partner funded and or supported sustainable ingredients programs, including biofragrances.

These are our nearest term revenue opportunity drivers with the clearest, most efficient path to market. This calibrated focus is designed to reduce our annual cash usage to approximately a net $30,000,000 by 2026, extending our runway while positioning us to capture the significant revenue opportunity ahead of us. That said, we have invested substantial resources and expertise in developing a portfolio of opportunity pipeline traits and programs that includes highly valuable productivity traits across multiple crops. We are actively in pursuit of partner funded projects for these traits until such time as our capital resources are sufficient to efficiently support more robust development efforts. I will now take a few moments to discuss our priority programs and recent regulatory progress before passing it over to Greg to discuss our opportunity pipeline traits and programs in more detail.

Starting with our RICE platform, which is our number one priority pipeline trait and foundation for near term revenue generation, we continue to make significant progress with trait integration, field trials, and registration activities, each of which are on track to meet our targeted commercial timelines. This quarter, we also achieved a key milestone by completing edits and delivering stacked traits containing our HT3 trait to a second U. S. Partner. Our customer momentum continues to build significantly.

Recently, we signed an agreement with Semilano, a Colombian based Latin American ripe seed company, marking our fifth customer in The Americas. The greater penetration of Latin America is particularly exciting, both with large and small participants, as these markets have historically lacked access to advanced weed management solutions in rice, representing a transformative opportunity for CBIS to drive value for farmers in these key regions with our gene edited HT traits. What’s driving this commercial interest is our standardized platform that enables us to edit customers’ elite germplasm and return it with specific traits in approximately twelve to fifteen months. This represents a fundamental breakthrough that intersects with agriculture’s important plant breeding programs, which, as I’ve said before, are the engine room of genetic innovation for the seed industry. Seed companies are coming to us because they recognize this creates a dependable model for trait development that is unlike anything the seed industry has seen before.

This is the recognition that our rapid trait development system accelerates the adoption of gene edited traits into their best genetics faster than modern trait integration. Field trial programs for rice are progressing as planned across our customer base, and we continue to advance trait registration activities that are essential for our Latin American launch target for 2027, 2028, and subsequent U. S. Commercialization targeted for 2028. We also expect to initiate our first trait validation trials in Latin America later this year, with delivery of initial HT traits to Latin American customers anticipated by year end.

Our partner funded and supported sustainable ingredients program continues to serve as a complementary near term revenue opportunity driver. We remain on track for nominal revenues from our biofragrance products beginning later this year, with targeted commercial expansion ramping in 2026. This quarter, we successfully completed first stage scale up of two biofragrance products, supporting our expectations for realizing revenues from this program. The biofragrance program continues to meet development milestones and demonstrates the versatility of our core capabilities in creating value beyond our crop productivity traits. What’s exciting about this area is the strong interest for bio based products we’re seeing from the consumer packaged goods industry.

The industry is very interested in our ability to provide fragrances and other products that they previously had to source through either expensive natural processes or synthetics. We expect the revenue ramp to accelerate in this area over the next few years, providing a near term offset to expenses as we advance our rice traits towards commercialization. Now shifting over to the regulatory front. We continue to see acceptance of gene editing technologies that is fundamentally changing the commercial landscape and the opportunity set for innovators such as CBIS. While the EU’s dialogue discussions have extended beyond their initial June 30 target this year, I want to emphasize that this process, while delayed, has not stalled, and customers remain engaged and excited about the opportunity that awaits.

The trialogue is a highly iterative process involving detailed committee work streams and negotiations among individual member countries, the parliament and the commission. These discussions are actively progressing, and we believe resolution will occur within the next six months. When completed, this will represent an incredible moment for our industry, one in which CBIS is uniquely positioned to benefit from due to our positive regulatory track record and commercial ready traits. The transition from Polish to Danish EU Council presidency has brought fresh momentum, with Danish officials having clear visibility on the specific outstanding items requiring resolution. This regulatory advancement, combined with our recent positive determination in Ecuador, ongoing approvals across North And South America, and continued regulatory clarity in India and parts of Asia, is creating a foundation to market traits globally.

These regulatory developments across multiple geographies significantly strengthen the commercial opportunity for our trait pipeline and serve as important catalysts for our business. And with that, I will now pass the call over to Greg to discuss our opportunity pipeline traits and programs. Greg?

Greg Gochel, Co-Founder and Chief Scientific Officer, CBIS: Thank you, Peter. Now before I share more details about our substantial opportunity pipeline, I would like to add my own endorsement of the breadth of the gene editing toolbox our talented team has developed here at CBIS. As a career plant biologist with over twenty five years experience in gene editing development, I continue to be impressed by the advances we make at CBIZ in our underlying editing frequency of gene editing at a cellular level. These advances paved the way for our commercial opportunities for the most important traits in our partners’ most elite seeds. Now, let me share more details about the substantial opportunity trait pipeline Peter just referenced.

Specifically our productivity traits portfolio and the partner interest we’re seeing across multiple programs. While we remain strategically focused on our priority near term revenue drivers, the value we’ve built in our broader trait portfolio continues to generate meaningful commercial opportunities that we’re well positioned to pursue through partnerships. I’ll briefly review some specific examples of the progress and partner interest we’re seeing, starting with our canola programs. Our HT2 field trials have delivered promising early results, validating both the traits tolerance profile and field efficacy. These positive field demonstrations have generated concrete interest from potential partners who recognize the significant commercial value of next generation herbicide tolerance in canola’s global market.

Remember, this is our second generation HT2 edits, which is a great example of how our technology can iterate and improve trait development. Equally compelling is our sclerotinia resistance program in canola, which continues to attract substantial interest. Potential partners are particularly drawn to our multilayered approach to durable disease resistance, an approach that addresses one of canola’s most persistent and costly challenges while offering growers a more sustainable solution. Beyond canola, our soybean platform represents perhaps our most substantial long term opportunity. Having successfully edited soybean cells for our HT2 trait earlier this year, we’ve made an initial step to demonstrate proof of concept to potentially access a market with an estimated 125,000,000 accessible acres, and potential annual trait royalties in the range of $10 to $15 per acre.

The scale of this opportunity, combined with our technical progress, has generated serious partnership discussions. More recently, we’ve realized a commercial milestone with our altered lignin alfalfa program. Last month, the FDA completed its review of our altered lignin alfalfa trait, clearing the way for U. S. Commercialization.

Our seed company customer is now positioned to offer the first commercial gene edited alfalfa varieties to U. S. Growers, with commercial seed quantities available in two initial variety offerings. This trait delivers compelling value by providing potentially improved digestibility for livestock while giving farmers greater harvest flexibility, essentially creating higher value alfalfa on the same acres with the same inputs. While not a significant potential revenue driver for us as compared to our priority programs such as rice and biofragrances, this successful partnership exemplifies our strategy of working with established seed companies to bring our traits to market efficiently while generating meaningful revenue streams for CBIUS.

What ties all of these programs together is the strong foundation we’ve built through our development activities, including ongoing greenhouse and field trials and the recent regulatory designations by the USDA APHIS of multiple CBIS traits as not regulated. This progress, combined with our demonstrated technical capabilities, positions us exceptionally well to engage partners who can provide both funding and market access for these valuable productivity traits. This partnership driven approach perfectly aligns with our capital discipline strategy Peter outlined, allowing us to advance these high value assets while maintaining our focused execution on priority revenue drivers. And with that, I’ll hand the call over to Carlo for a financial update. Carlo?

Carlo Bruich, Interim Chief Financial Officer, CBIS: Thank you, Greg. Looking at our financials for the second quarter, our cash and cash equivalents were 36,500,000.0 as of 06/30/2025. Taking into account the 27,500,000.0 in gross proceeds we raised from our public offering in June, along with the impact of implemented cost saving initiatives, we expect that our existing cash and cash equivalents will be sufficient to fund planned operating expenses and capital expenditure requirements into the second quarter twenty twenty six. Moving to our operating results. Revenue for the second quarter was 933,000 compared to 838,000 in the year ago period, reflecting increased activity in our partner funded programs.

Research and development expense was 12,200,000.0 for the second quarter compared to 13,000,000 in the year ago period. This 800,000 decrease is primarily due to cost reduction initiatives that we have implemented as part of our streamlined operational focus. Selling, general, and administrative expense was 6,600,000.0 for the second quarter, compared to 9,300,000.0 in the year ago period. The 2,700,000.0 decrease is primarily due to cost reduction initiatives. Net loss was 26,600,000.0 for the second quarter, compared to 28,500,000.0 in the year ago period.

As Peter mentioned, we’re focused on managing our cash usage as we approach revenue generation. Subsequent to quarter end, we announced a reduction in force as a pivotal step in implementing our streamlined business focus. We expect this RIF to result in related one time charges of approximately 500,000.0 in the third quarter. However, the RIF, along with other initiatives, is expected to reduce our annual net cash usage to approximately 30,000,000 by 2026. This disciplined approach to capital allocation extends our cash runway, while positioning us to capture the significant revenue opportunity ahead of us, with initial revenues beginning in 2026 and meaningful commercial expansion thereafter.

And with that financial overview, let me turn it back to Peter for closing remarks.

Peter Beetham, Co-Founder, Interim CEO, President and COO, CBIS: Thank you, Carlo. As I reflect on our progress this quarter and look ahead, I’m really confident we’re executing on the strategy that will deliver long term value for our shareholders. Our team has made some tough decisions this past quarter, and I’d like to recognize the entire team for their impactful contributions. While difficult, this has positioned us to stay laser focused on the commercial path in front of us as we pursue our long term strategy. We see this as a natural evolution of our business, as our partner interactions are now more focused on delivering traits in a time bound and predictable way.

As I noted previously, improved genetics are the engine room to seed genetic advancement, driving real value creation for farmers, our seed company partners, and for CEBA shareholders. The bottom line is we have traits moving into customer germplasm. We continue to see positive field trial results, and we’re operating in an increasingly favorable regulatory environment that’s opening up global market opportunities. The gene editing revolution in agriculture is happening now, and SEVIS is positioned at the forefront of this transformation with a clear path to approximately $200,000,000 in potential annual royalty revenue from our rice traits alone, with initial biofragrance revenues beginning next fiscal year and meaningful expansion as we progress through to our rice commercial launch timeline. As I’ve mentioned a few times, we remain laser focused on our core priorities, advancing our rice herbicide tolerance traits toward commercialization, growing our partner funded and supported sustainable ingredients program, and building the operational foundation for sustainable revenue and cash flow generation that will capture significant value as our market opportunities materialize.

We are confident that in time, the gene editing opportunities will expand to many of the world’s important fruit crops. In concert with this and with the advent of AI and tools like gene editing to execute on complex traits, we do see expanding trait development categories opening up like nutrient use efficiency, NUE, and the exciting opportunities of nonallergenic crops. And with that small look into the future, thank you all for your attention and interest, and we look forward to updating you on our continued progress next quarter. Operator, we’re now ready to take questions.

Conference Operator: Thank you. At this time, if you would like to ask a question, please press star one on your telephone keypad. You may remove yourself from the queue at any time by pressing star two. We will go first to Matthew Venizio with AGP.

Matthew Venizio, Analyst, AGP: Hey, guys. Thank you for taking my questions. First, I wanted to ask about the germplasm transfer that occurred this quarter. So, is this a customer that has already initiated field trials in Rice HT3 on their own? Or would this provide a new set of company specific field trials?

And then I have a couple of follow ups.

Peter Beetham, Co-Founder, Interim CEO, President and COO, CBIS: Thanks, Matt. This is Peter. I really appreciate your question. You know, just to put this into context, I think this is a great example of why we’re so excited about Ross. I think that we’re on the commercial path now, with six customers.

And our ability to do edits and get material back to customers is something we’re really proud of, and I think that is really going to set us up for the future. But more specifically around your question, I think this is something I’m going to hand off to Greg because he’s been intimately involved in the delivery of these lines back to one of our existing rights customers.

Greg Gochel, Co-Founder and Chief Scientific Officer, CBIS: Yeah. Thanks, Peter, and thanks, Matt, for the question. So this is a new customer that we’re delivering back to for The US, and we’re delivering back multiple lines with our HK3 trait. So we’re really excited because of their ability then to use that in field trials going forward.

Matthew Venizio, Analyst, AGP: Great. Okay. Thank you, Greg. That answers my question. And then I heard at the beginning of the call, you had mentioned initial revenue in 2026.

Is this reflecting the Biofragrance moving from 4Q twenty twenty five into 1Q twenty twenty six for those first nominal revenues?

Peter Beetham, Co-Founder, Interim CEO, President and COO, CBIS: Thanks, Matt. Let me expand on that a little bit because I think this is an area of our business that is, again, really looking forward to getting our first revenues. And what we’ve been really focused on, as you’ll hear more and more around CBIS, is that we’re so laser focused on that near term revenue. So with regards to the biofragrances, you know, as as you’ve heard, we’ve had a lot of success over the last quarter of starting to scale up. And everything we’ve done, we’ve met our milestones on scale up.

We’re really excited about the where we’re at now and where we’re going to be towards the end of this year. We still see some nominal revenues this year, as we scale up as some of the early product is delivered back to a customer. And then in ’26 is when we really start to do full commercial runs with regard to the bio fragrances that we have in our pipeline. And from there, there it really ramps beyond that.

Matthew Venizio, Analyst, AGP: Great. Thank you. And those biofragrance revenues are all royalty in the same way your other potential revenues would be, correct?

Peter Beetham, Co-Founder, Interim CEO, President and COO, CBIS: Correct. I mean, the nominal revenues to start with, we’re handing off some of the scale up material, which is great. So that’s not essentially a royalty, but next year, we’ll be moving to the royalty business model.

Matthew Venizio, Analyst, AGP: Great. Okay. Thank you guys for taking my questions. I’ll hop back in the queue.

Peter Beetham, Co-Founder, Interim CEO, President and COO, CBIS: Thanks, Matt.

Conference Operator: We’ll go next to Austin Moeller with Canaccord.

Austin Moeller, Analyst, Canaccord: Hi, good afternoon. Just my first question here. What have the Danish officials in European Parliament told you are the next steps or hurdles in the negotiations for approving gene editing in the EU?

Peter Beetham, Co-Founder, Interim CEO, President and COO, CBIS: Austin, thank you for your question. This is Peter. I’m gonna start off and I’ll let Greg chime in as well. But I think, as I said in our prepared remarks, the EU regulatory acceptance is something that is part of the harmonizing globally. And that really has turned what has been some headwinds into tailwinds.

I can’t stress that enough. It is it is really why, you know, gene editing is happening now and a clear path for our commercialization of many traits. So, you know, obviously, we follow this closely. And, as the trialogue goes forward, it is a highly iterative process. There’s a number of detailed committee work streams, based on council, the parliament, and the commission.

And to your question around the Danish, what we’ve heard from, both the Polish and the Danish is that they’re really working on the the important amendments that were tabled last year in parliament. And what they’re looking at is how to implement the legislation and get to the final text. So some of that is around understanding how to execute that in all the different countries. And so some of the questions that have been brought up and the visibility around that is with regards to labeling and patenting, two of the key issues that they’ve discussed. And I think that, the good news for all of us in the technology space is that that’s really being handled very, carefully and linked with the European Patent Office.

So we’re confident that in the next six months, these will come to a good resolution, and we’ll have a final text by the end of this year.

Greg Gochel, Co-Founder and Chief Scientific Officer, CBIS: Just to add a little bit to Peter’s remarks. So remember that we’ve been in field trials in The UK with our pod shatter resistance trait for the last two years. And what you’ve seen in The UK is a move from approved legislation to implementing that legislation over the last couple of years to get to the point where you’ll shortly be able to plant and grow edited crops without any restriction in in The UK, and that’s our expectation going forward once you have final text in in The EU and it’s implemented across all of the all of the 27 countries. So thanks. Thanks for the question, Austin.

Austin Moeller, Analyst, Canaccord: Thanks. And just to follow-up, what stage are we at in the winter oilseed rate field trials in The UK? And what is the timeline for evaluation of the results?

Greg Gochel, Co-Founder and Chief Scientific Officer, CBIS: So we’re towards the end of the second field season. So harvest will happen likely in August, and that’s where we’ll know what the efficacy of the traits this year is. But we’re excited from what we saw last year that those results are similar this year for the material that was planted.

Austin Moeller, Analyst, Canaccord: Great. Thanks for the additional details.

Greg Gochel, Co-Founder and Chief Scientific Officer, CBIS: Thanks, Austin.

Conference Operator: We’ll go next to Sameer Joshi with H. C. Wainwright.

Sameer Joshi, Analyst, H.C. Wainwright: Yeah, good afternoon, and thanks for taking my questions. I just have a quick couple ones, mostly focused on 2026 cash burn. So I

Peter Beetham, Co-Founder, Interim CEO, President and COO, CBIS: think

Sameer Joshi, Analyst, H.C. Wainwright: you are on track to reduce your OpEx to 13,000,000 by the end of next year. When should we start seeing that like, drop in expense? And part two of that question is, are you assuming any net proceeds from the biofragrances business that you expect to commercialize next year?

Peter Beetham, Co-Founder, Interim CEO, President and COO, CBIS: So thanks, Samir. This is Peter. I’ll start out and hand off to Carlo. But I think, you know, what we said in our prepared remarks too is that, you know, we’re very much focused on a disciplined and strategic approach to our capital allocation. And excuse me.

And this this is a natural evolution of how the business, is evolved. You know, as we move and see a clear path to commercialization, we’re really about maximizing our near term opportunities. And I think, you know, both bio fragrances and the rice traits, there’s some every day we see a clearer path, which is fantastic. What we’ve also recognized is that to focus on that, our business model is changing. And this is a really important point for everybody to hear, that you know, our ability to do things time bound and predictably with editing and to be able to hand back to customers earlier has really changed the way we think about, the business and what we do.

And part of that is handing off earlier to customers, like we talked about, with regards to our rights customers in HT3, allows us to really sort of be more strategic and disciplined about our our capital allocation. So, you know, over the next couple of months, we’ve already seen a reduction in spend. You know, we had a reduction in force subsequent to quarter end, and we’re on track to reduce our annual net cash usage, as you mentioned, in 2026 to a net $30,000,000. No. This is part of the natural evolution of the business, and it also is part of our laser focus.

And I’ll hand it to Carlo to see if he wanted to add anything.

Carlo Bruich, Interim Chief Financial Officer, CBIS: Yeah. Thank you, Peter. Now you fully nailed it. The riff, as you have have heard and as you can read, was in July. And the focus we talk about this is absolutely also on expenses and takes now a bit of time, but we’re focused to be ready early twenty six the number you mentioned.

So the 30,000,000 is a net number, and that is our target for 2026, and we get there. Thanks, Amir.

Sameer Joshi, Analyst, H.C. Wainwright: Understood. And my second question relates to sort of the scale up and scale of sustainable ingredients. Like, when should we see, meaning apart from the biofragrances, the sustainable ingredients and maybe also consumer packaged goods start to at least see some commercial or customer interaction, And when should we see the scale up in revenues from those?

Peter Beetham, Co-Founder, Interim CEO, President and COO, CBIS: Thank you for the question. Let me I’ll start out on this one and then hand off to Greg. But I think there’s two parts to your question. There’s the fragrances, and this is, definitely where we see the scale up, from ’26, through the next eighteen months on that. And I think that that’s exciting for us because it really helps to, you know, work through to revenues that are meaningful very quickly.

And that’s the beauty of, that particular revenue stream. With regards to sustainable ingredients, we are in the process of working with a funding partner, and we’ve made a lot of progress in that area. We’re excited to see that come, but probably not for a couple of years. And so I think that’ll be towards the ’20 in the late 20s is the best I could say today. But the good news is, in the sustainable ingredients area, is this is an expanding space.

Bio based products, whether it’s fragrances or other bio based products, is an area that has really garnered a lot of interest in agriculture, and it continues to. So it’s not just fuels anymore. There’s lots of other sustainable ingredients that people fascinated to to apply new technologies to. And gene editing is one of the technologies that allows you to think through really interesting products that are all different oil profiles, for example. And I mentioned in some of the summary remarks about nonallergenic crops as well, nonallergenic peanuts, nonallergenic wheat.

These are opportunities that are really important sustainable ingredients as we go forward. And Greg, go

Greg Gochel, Co-Founder and Chief Scientific Officer, CBIS: Yeah. So Peter, I think you’ve covered most of it. So I think the bottom line is we’re leveraging the platforms that we have, and really we have a lot of opportunities in platforms that we’ve developed in the past, as Peter says, with opportunities potentially in wheat and peanut, but also an ability to really understand the what to edit for a vast number of traits. We’re on more of the output side of the traits. What we would see is those are done mainly with partnerships, and even as we move forward with our Sclerotinia program and our HT2 program, we see those as partnered activities where we’ve made a huge amount of progress that we can really quickly deploy with managing our cash into potential products in the future.

So thank you for your question.

Carlo Bruich, Interim Chief Financial Officer, CBIS: Yeah, no, thank you.

Sameer Joshi, Analyst, H.C. Wainwright: Thanks for that color. That was very useful. Thanks for taking my questions.

Conference Operator: We will go next to Laurence Alexander with Jefferies.

Kevin, Analyst, Jefferies: Hey guys, this is Kevin on for Laurence. Thank you for taking my questions. So just on the EU regulatory discussions, I mean, I guess how long do you think it could be until companies are either selling into the EU or going to third party customers that then sell into the EU via trade? And I guess have you sort of quantified what you think the opportunity, I guess, for the EU could represent to you guys? And just really quick last on that, what do you think could be the larger opportunity?

Would it be domestic cultivation in the EU or or trade of gene edited crops into the EU?

Peter Beetham, Co-Founder, Interim CEO, President and COO, CBIS: Thanks, Kevin. This is Peter. I’ll start out. I think that the EU, as I mentioned on the regulatory front, you know, again, it’s something we follow so closely. Know, because we’ve been doing this for a number of years.

So we understand that literally in the next six months, there will be legislation and final text. There’s no doubt in our minds that that is the likely outcome of where the Danish What that triggers is the implementation side of it. And so the just as what has happened in The UK, if we go back and look at what happened with The UK, they went through the primary legislation and then the secondary legislation, which is essentially to implement, that law. And we see that, probably two years after the final text, and so that’ll be heading towards the ’27 is when you’ll start to see, products that can be, commercialized in that marketplace. Primarily, it’s to do a seed variety registration work that’ll be done in the EU.

But more importantly is what you’ll see, as you saw in The UK and what you’ve already seen in parts of Italy, is gene edited field trials will start to occur next year with some partners. And so as well as, mox cultivation as field trials will start happening, that’ll pave the way for full commercialization. And remember, Europe is literally in crops. There’s a 100,000,000 acre opportunity, greenfield opportunity when it comes to traits. You know, they missed out on traits because, they banned essentially banned GMOs, and so they haven’t had the ability to take any trades into that marketplace.

So I think, you know, not only does EU drive a lot of positivity around global regulatory harmonization for trade and for cultivation, but it also opens up this enormous marketplace for traits we move forward. So we’re really excited about, you know, not only just for our near term revenue opportunities, but also the longer term where we can access that market.

Kevin, Analyst, Jefferies: Understood. Okay. Thank you. And then just on RTDS, I guess just more generally, I guess how is GIVUS differentiating its technology amid the rising competition in gene editing in general?

Greg Gochel, Co-Founder and Chief Scientific Officer, CBIS: Yeah. So Kevin, I think that’s an excellent question. I mean, we’re really excited. In terms of the RTDS system, we’re starting with single cells and editing those single cells in a process and to generate a product that is non transgenic. So that is our approach and having built gene editing from the ground up.

But even beyond that, it’s the complex edits, so both numbers of loci. So we had a paper published at the ’3 talking about eight different loci. We continue to push the limits of how many loci we can edit in a single cell at the same time, and you’ll understand that with a process where you don’t need a null segregate, you keep your genetic configuration intact as you move that forward. The second part is continuing to increase the number of edits collinear in a locus, And I think for what’s possible in plants, I think we’re in the best place from what I see out in the peer reviewed literature and at conferences, etcetera. So we’re excited for the complexity of the edits that we can make and the single cell system that enables us to keep those edits together in the right genetic configuration in a lead germ plasmid.

Peter Beetham, Co-Founder, Interim CEO, President and COO, CBIS: Me just add a little bit to that, Kevin, because I think it’s such an important question, and I’m gonna maybe simplify it a little bit. No one else does what we do. Using the single cell system has huge advantages for complex traits, but also from a regulatory front. So it’s something that, just as Greg said, we’ve built this from the ground up as a gene editing company, not really changing a GMO pipeline into an editing pipeline. So there’s a we are very different to anybody else and creates a lot of opportunities that no one else can get to.

Kevin, Analyst, Jefferies: Okay. Thank you very much. I appreciate it.

Peter Beetham, Co-Founder, Interim CEO, President and COO, CBIS: Thanks, Kevin.

Conference Operator: We will go next to Alex Hammond with Sidoti.

Alex Hammond, Analyst, Sidoti: Good afternoon. Thanks for taking questions. Just a couple from me. Firstly, a follow-up on the ’26 commercial ramp for biofragrance. Could we just talk a little bit about whether that comes from expanding your relationship with your current client or is that really from selling into new customers and so that might take a little longer?

Peter Beetham, Co-Founder, Interim CEO, President and COO, CBIS: Thanks, Alex. This is Peter. That’s such a great question because it really is a big driver. We are very much focused on, a single customer right now for 2026. Having said that, you know, we there is other opportunities out there.

And fragrances are used in so many different products from personal care to packaging to a lot of household goods. And that size of market continues to grow when you can provide something that’s bio based and not necessarily you know, through very expensive natural processes or synthetic processes. So you’ve got an opportunity that we see potentially expanding. But to your specific question in ’26, it is really around one customer. We’d like to see that expand even within that customer’s opportunity, and take on others as well.

Alex Hammond, Analyst, Sidoti: Great context, thank you. And then one more from me, just on something you’ve brought up a couple times. So I think you gave a sense of royalty scale for alfalfa relative to rice, but maybe you could do the same for, you know, nonallergenic crops and nitrogen use efficiency.

Peter Beetham, Co-Founder, Interim CEO, President and COO, CBIS: Thanks, Alex. Yeah. Exactly. You know, I think that when you think about Cebus from a commercialization company, we’re all about licensing technology for royalties. And so we’re also very much focused on productivity traits.

So every productivity trait we think about is what the money that we are going to save the farmer at the farm gate. So that’s where our annualized royalty pricing comes from. I think that when you start to do complex traits or you start to combine traits and bring traits together, the pricing model increases. And it’s exciting to see the sorts of numbers you might get to when you think about what Greg mentioned earlier about the 10 to $15 per acre next to see this on a trait in soybean. You know, that we think can access 125,000,000 acres.

The when it comes to nonallergenic crops, the pricing as a royalty can be considerably more than that because you end up with a quality trait that it’s garnish a much higher premium, not only at the farm gate, but when they deliver it to silos or they deliver it to a food company. So I think that we are yet to sort of talk about any pricing in those sorts of areas that we have in our productivity traits. But suffice to say, I think some of the quality traits are going to have a much higher price point from a royalty standpoint.

Alex Hammond, Analyst, Sidoti: Understood. Thank you.

Peter Beetham, Co-Founder, Interim CEO, President and COO, CBIS: Thank you.

Conference Operator: And we have no further questions holding at this time. I will now turn the conference back to Peter Beetham for any additional or closing remarks.

Peter Beetham, Co-Founder, Interim CEO, President and COO, CBIS: So thank you, for everybody to join the call today. I really do appreciate that. I’ve just got a few closing remarks because I think we’ve covered a lot today. But I wanted to say how proud I was of the team in the last quarter. This is a time where the business is evolving, and I couldn’t be prouder of what we’ve been able to achieve, but also positioning us for commercial success.

Implementing changes to maximize our path to that near term revenue is something that everyone in this company has been laser focused on. I couldn’t be prouder of that. What I’ve said before, and I’ll say it again, is gene editing has a clear path to industrialized breeding. And it’s not for the future. It’s actually happening now, which is very exciting.

So hopefully, we’ve covered a good, summary of our pipeline, where we are laser focused with Rice and beyond. I think Greg’s done a great job of sharing out our portfolio. And as a group, we look forward to updating you all on the next earnings call next quarter. So I’d like to thank you for your interest, and thank you for your continued support. And with that, we would like to close the call.

Thank you.

Conference Operator: Thank you, sir. This does conclude today’s program. We thank you for your participation. You may disconnect at any time.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.